Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2013

Open Access 01-12-2013 | Case report

An autoinflammatory neurological disease due to interleukin 6 hypersecretion

Authors: Ettore Salsano, Ambra Rizzo, Gloria Bedini, Loris Bernard, Valentina Dall’Olio, Sara Volorio, Monica Lazzaroni, Isabella Ceccherini, Dejan Lazarevic, Davide Cittaro, Elia Stupka, Rosina Paterra, Laura Farina, Mario Savoiardo, Davide Pareyson, Francesca L Sciacca

Published in: Journal of Neuroinflammation | Issue 1/2013

Login to get access

Abstract

Autoinflammatory diseases are rare illnesses characterized by apparently unprovoked inflammation without high-titer auto-antibodies or antigen-specific T cells. They may cause neurological manifestations, such as meningitis and hearing loss, but they are also characterized by non-neurological manifestations. In this work we studied a 30-year-old man who had a chronic disease characterized by meningitis, progressive hearing loss, persistently raised inflammatory markers and diffuse leukoencephalopathy on brain MRI. He also suffered from chronic recurrent osteomyelitis of the mandible. The hypothesis of an autoinflammatory disease prompted us to test for the presence of mutations in interleukin-1−pathway genes and to investigate the function of this pathway in the mononuclear cells obtained from the patient. Search for mutations in genes associated with interleukin-1−pathway demonstrated a novel NLRP3 (CIAS1) mutation (p.I288M) and a previously described MEFV mutation (p.R761H), but their combination was found to be non-pathogenic. On the other hand, we uncovered a selective interleukin-6 hypersecretion within the central nervous system as the likely pathogenic mechanism. This is also supported by the response to the anti-interleukin-6−receptor monoclonal antibody tocilizumab, but not to the recombinant interleukin-1−receptor antagonist anakinra. Exome sequencing failed to identify mutations in other genes known to be involved in autoinflammatory diseases. We propose that the disease described in this patient might be a prototype of a novel category of autoinflammatory diseases characterized by prominent neurological involvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621–668.CrossRefPubMedPubMedCentral Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621–668.CrossRefPubMedPubMedCentral
2.
go back to reference Aksentijevich I, Kastner DL: Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 2011, 7:469–478.CrossRefPubMed Aksentijevich I, Kastner DL: Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 2011, 7:469–478.CrossRefPubMed
3.
go back to reference Karachaliou I, Karachalios G, Charalabopoulos A, Charalabopoulos K: Meningitis associated with familial Mediterranean fever. Int J ClinPractSuppl 2005, 147:60–61. Karachaliou I, Karachalios G, Charalabopoulos A, Charalabopoulos K: Meningitis associated with familial Mediterranean fever. Int J ClinPractSuppl 2005, 147:60–61.
4.
go back to reference Kitley JL, Lachmann HJ, Pinto A, Ginsberg L: Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 2010, 74:1267–1270.CrossRefPubMed Kitley JL, Lachmann HJ, Pinto A, Ginsberg L: Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 2010, 74:1267–1270.CrossRefPubMed
5.
go back to reference Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581–592.CrossRefPubMedPubMedCentral Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581–592.CrossRefPubMedPubMedCentral
6.
go back to reference Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, Hessner MJ, Verbsky J: An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009, 360:2438–2444.CrossRefPubMedPubMedCentral Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, Hessner MJ, Verbsky J: An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009, 360:2438–2444.CrossRefPubMedPubMedCentral
7.
go back to reference Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, Barron KS, Holland SM, Kastner DL, Aksentijevich I: Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009, 60:1851–1861.CrossRefPubMedPubMedCentral Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, Barron KS, Holland SM, Kastner DL, Aksentijevich I: Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009, 60:1851–1861.CrossRefPubMedPubMedCentral
8.
go back to reference Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, Pelagatti MA, D'Osualdo A, Buoncompagni A, Alpigiani MG, Alessio M, Martini A, Rubartelli A: Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007, 56:3138–3148.CrossRefPubMed Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, Pelagatti MA, D'Osualdo A, Buoncompagni A, Alpigiani MG, Alessio M, Martini A, Rubartelli A: Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007, 56:3138–3148.CrossRefPubMed
9.
go back to reference Kestner M, Rosler AE, Baumgärtner M, Lindner A, Orth M: CSF interleukin 6 – a useful biomarker of meningitis in adults?/Liquor Interleukin 6 – einsinnvoller Biomarker für die Meningitis beimErwachsenen. Laboratoriums Medizin 2011, 35:107–113.CrossRef Kestner M, Rosler AE, Baumgärtner M, Lindner A, Orth M: CSF interleukin 6 – a useful biomarker of meningitis in adults?/Liquor Interleukin 6 – einsinnvoller Biomarker für die Meningitis beimErwachsenen. Laboratoriums Medizin 2011, 35:107–113.CrossRef
10.
go back to reference Hashizume M, Higuchi Y, Uchiyama Y, Mihara M: IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 2011, 54:92–99.CrossRefPubMed Hashizume M, Higuchi Y, Uchiyama Y, Mihara M: IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 2011, 54:92–99.CrossRefPubMed
11.
go back to reference Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959–3964.CrossRefPubMed Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959–3964.CrossRefPubMed
12.
go back to reference Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693–706.CrossRefPubMedPubMedCentral Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693–706.CrossRefPubMedPubMedCentral
14.
go back to reference Singh-Grewal D, Chaitow J, Aksentijevich I, Christodoulou J: Coexistent MEFV and CIAS1 mutations manifesting as familial Mediterranean fever plus deafness. Ann Rheum Dis 2007, 66:1541.CrossRefPubMedPubMedCentral Singh-Grewal D, Chaitow J, Aksentijevich I, Christodoulou J: Coexistent MEFV and CIAS1 mutations manifesting as familial Mediterranean fever plus deafness. Ann Rheum Dis 2007, 66:1541.CrossRefPubMedPubMedCentral
15.
go back to reference Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993, 90:10061–10065.CrossRefPubMedPubMedCentral Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993, 90:10061–10065.CrossRefPubMedPubMedCentral
16.
go back to reference Brett FM, Mizisin AP, Powell HC, Campbell IL: Evolution of neuropathologic abnormalities associated with blood–brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995, 54:766–775.CrossRefPubMed Brett FM, Mizisin AP, Powell HC, Campbell IL: Evolution of neuropathologic abnormalities associated with blood–brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 1995, 54:766–775.CrossRefPubMed
17.
go back to reference Wakabayashi K, Fujioka M, Kanzaki S, Okano HJ, Shibata S, Yamashita D, Masuda M, Mihara M, Ohsugi Y, Ogawa K, Okano H: Blockade of interleukin-6 signaling suppressed cochlear inflammatory response and improved hearing impairment in noise-damaged mice cochlea. Neurosci Res 2010, 66:345–352.CrossRefPubMed Wakabayashi K, Fujioka M, Kanzaki S, Okano HJ, Shibata S, Yamashita D, Masuda M, Mihara M, Ohsugi Y, Ogawa K, Okano H: Blockade of interleukin-6 signaling suppressed cochlear inflammatory response and improved hearing impairment in noise-damaged mice cochlea. Neurosci Res 2010, 66:345–352.CrossRefPubMed
18.
go back to reference Nishimura H, Strominger JL: Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. ProcNatlAcadSci USA 2006, 103:3292–3297.CrossRef Nishimura H, Strominger JL: Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. ProcNatlAcadSci USA 2006, 103:3292–3297.CrossRef
19.
go back to reference Solomon DH, Kavanaugh AJ, Schur PH: American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines: Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002, 47:44–434.CrossRef Solomon DH, Kavanaugh AJ, Schur PH: American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines: Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002, 47:44–434.CrossRef
20.
go back to reference Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542–552.CrossRefPubMedPubMedCentral Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542–552.CrossRefPubMedPubMedCentral
22.
go back to reference Prabhakaran S, Bramlage M, Edgar MA, Diamond B, Hardin JA, Volpe BT: Overwhelming leukoencephalopathy as the only sign of neuropsychiatric lupus. J Rheumatol 2005, 32:1843–1845.PubMed Prabhakaran S, Bramlage M, Edgar MA, Diamond B, Hardin JA, Volpe BT: Overwhelming leukoencephalopathy as the only sign of neuropsychiatric lupus. J Rheumatol 2005, 32:1843–1845.PubMed
25.
go back to reference Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K: Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002, 31:205–210.CrossRefPubMed Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K: Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002, 31:205–210.CrossRefPubMed
26.
go back to reference Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA: Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008, 149:284–286.CrossRefPubMed Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA: Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008, 149:284–286.CrossRefPubMed
27.
go back to reference Birnbaum J, Hellmann DB: Primary angiitis of the central nervous system. Arch Neurol 2009, 66:704–709.CrossRefPubMed Birnbaum J, Hellmann DB: Primary angiitis of the central nervous system. Arch Neurol 2009, 66:704–709.CrossRefPubMed
Metadata
Title
An autoinflammatory neurological disease due to interleukin 6 hypersecretion
Authors
Ettore Salsano
Ambra Rizzo
Gloria Bedini
Loris Bernard
Valentina Dall’Olio
Sara Volorio
Monica Lazzaroni
Isabella Ceccherini
Dejan Lazarevic
Davide Cittaro
Elia Stupka
Rosina Paterra
Laura Farina
Mario Savoiardo
Davide Pareyson
Francesca L Sciacca
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2013
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-10-29

Other articles of this Issue 1/2013

Journal of Neuroinflammation 1/2013 Go to the issue